Opus Genetics, Inc.
Developing gene therapies for inherited retinal diseases and other blinding conditions.
IRD | NDAQ
Overview
Corporate Details
- ISIN(s):
- US67577R1023 (+2 more)
- LEI:
- Country:
- United States of America
- Address:
- 8 DAVIS DRIVE, 27713 DURHAM
- Website:
- https://opusgtx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Opus Genetics, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other retinal disorders. The company's pipeline targets specific genetic mutations that cause vision loss, with programs addressing conditions such as Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa (RP). Opus aims to build a scalable engine to efficiently develop and advance new treatments for a wide range of inherited blinding conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Opus Genetics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Opus Genetics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Opus Genetics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
